{ "as_of": "2026-11-06", "cmr": "dk-cm-kg/XCSE/DK0010272202", "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.", "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# Genmab A/S (Nasdaq Copenhagen: DK0010272202) — research page\n\nAs of 2026-11-06 · dk-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is Genmab A/S, listed on Nasdaq Copenhagen under ticker DK0010272202, with ISIN DK0010272202 and LEI 529900MTJPDPE4MHJ122. Security type, segment, sector and jurisdiction are not on the record. Listing status is listed, not halted.\n\n## The disclosure read\n\nThe record holds 91 filings on 74 filing days in the window 2025-11-06 to 2026-11-06. The median gap between filing days is 3 days, and the median latency from the latest filing to the record date is 1 day. Nasdaq Copenhagen has 119 issuers with a median cadence gap of 8.0 days, a median of 25 filings and a median latency of 4.0 days. Sector peer figures are not on record for this market. The latest filing is an Interim report (Q1 and Q3) dated 2026-11-05.\n\n## Auditor\n\nThe auditor of record and its location are not on the record. Auditor changes are not on the record, as this register has no lifecycle type map yet.\n\n## Events and halts\n\nListing, delisting, name change, domicile change and segment move are not on the record, as this register has no lifecycle type map yet. The issuer is listed and not halted.\n\n## Orderability\n\nThe outcome is not determinable under rule version acm-68000/dk/mifid-ii-product-governance/r1, because the chapter's orderability section, as of 2026-11-04, carries no client categories.\n\n## Coverage\n\nNo research houses were found on the issuer's investor-relations pages read.\n\n## Open research\n\nNo openly published research notes were found on the record.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe market's vintage is not sealed, and no issuer years are sealed. The market's earliest sealed date is not on the record, and the live record began date is not on the record.\n\n## Sources\n\n6 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://firds.esma.europa.eu/firds/ (identity.exchange)\n- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)\n- https://mcp.dk-cm-kg.ai/events/XCSE/DK0010272202 (the disclosure lines)\n- https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=exchangeNewsFilterCPH|FirstNorthInformationCPH (the halt flag)\n- https://dk.eu-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://mcp.dk-cm-kg.ai/record/XCSE/DK0010272202 (the record)\n", "market": "DK", "node": "dk-cm-kg", "numbers": { "as_of_depth": { "issuer_years_sealed": [], "live_record_began": null, "node_history_from": null, "node_years_sealed": [], "note": "the DK vintage is not sealed; the record is the live record as of 2026-11-06", "record_version": 1, "sealed": false }, "auditor": { "auditor": { "market": "DK", "state": "not_on_record" }, "auditor_firm_id": { "market": "DK", "state": "not_on_record" }, "auditor_location": { "market": "DK", "state": "not_on_record" }, "changes": { "market": "DK", "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)", "state": "not_on_record" } }, "cmr": "dk-cm-kg/XCSE/DK0010272202", "coverage": { "count": 0, "houses": [], "pages_checked": [ { "page": "https://ir.genmab.com/analyst-coverage/", "result": "not readable by this rail (403)" } ], "read_by": "Perplexity sonar (search) · page read by this rail", "read_date": "2026-11-12", "since": null, "state": "none_found" }, "disclosure": { "against": { "exchange": { "issuers": 119, "median_cadence_gap_days": 8, "median_filings": 25, "median_latency_days": 4, "name": "Nasdaq Copenhagen" }, "sector": { "market": "DK", "state": "not_on_record" } }, "by_type": { "Annual Financial Report": 1, "Articles of association": 13, "Changes in company's own shares": 5, "Decisions of general meeting": 2, "Half Year financial report": 1, "Inside information": 11, "Interim report (Q1 and Q3)": 3, "Investor News": 25, "Major shareholder announcements": 6, "Managers' Transactions": 8, "Notice to general meeting": 2, "Other information disclosed according to the rules of the Exchange": 7, "Total number of voting rights and capital": 7 }, "cadence_median_gap_days": 3, "filing_days": 74, "filings": 91, "latency_days": 1, "latest": [ { "category": "Interim report (Q1 and Q3)", "date": "2026-11-05", "source": "https://view.news.eu.nasdaq.com/view?id=bba6f1132eadb55328d51bb0071b3ee74&lang=en&src=listed", "title": "Genmab Announces Financial Results for the Nine Months of 2026", "type": "Interim report (Q1 and Q3)" }, { "category": "Investor News", "date": "2026-11-04", "source": "https://view.news.eu.nasdaq.com/view?id=b1affffb68950e3efcc5d33530596aad8&lang=en&src=listed", "title": "Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting", "type": "Investor News" }, { "category": "Inside information", "date": "2026-10-28", "source": "https://view.news.eu.nasdaq.com/view?id=bc127e43bd77fb37a8de16dc38e63be46&lang=en&src=listed", "title": "Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer ", "type": "Inside information" }, { "category": "Investor News", "date": "2026-10-26", "source": "https://view.news.eu.nasdaq.com/view?id=b9873b7e611ae42e4dd1de229da453777&lang=en&src=listed", "title": "Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma", "type": "Investor News" }, { "category": "Investor News", "date": "2026-10-25", "source": "https://view.news.eu.nasdaq.com/view?id=b6095572e207eaebe8fa3f74f79055b9f&lang=en&src=listed", "title": "Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer", "type": "Investor News" } ], "latest_filing_date": "2026-11-05", "read": "the node's event lines (list_events_since), as get_filings serves them", "source": "https://mcp.dk-cm-kg.ai/events/XCSE/DK0010272202", "window": { "from": "2025-11-06", "to": "2026-11-06" } }, "identity": { "exchange": { "read_by": "allooloo-cm-kg/eu-sources/dk roster.py", "read_date": "2026-11-06", "read_date_basis": "the record version as_of", "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)", "state": "sourced", "value": "Nasdaq Copenhagen" }, "isin": { "read_by": "allooloo-cm-kg/eu-sources/dk roster.py", "read_date": "2026-11-06", "read_date_basis": "the record version as_of", "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)", "state": "sourced", "value": "DK0010272202" }, "jurisdiction": { "market": "DK", "state": "not_on_record" }, "lei": { "read_by": "GLEIF ISIN-to-LEI mapping file (daily), LEI by exact ISIN", "read_date": "2026-11-09", "read_date_basis": "the field", "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download (ISIN DK0010272202)", "state": "sourced", "value": "529900MTJPDPE4MHJ122" }, "name": { "read_by": "allooloo-cm-kg/eu-sources/dk roster.py", "read_date": "2026-11-06", "read_date_basis": "the record version as_of", "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)", "state": "sourced", "value": "Genmab A/S" }, "sector": { "market": "DK", "state": "not_on_record" }, "security_type": { "market": "DK", "state": "not_on_record" }, "segment": { "market": "DK", "state": "not_on_record" }, "ticker": { "read_by": "allooloo-cm-kg/eu-sources/dk roster.py", "read_date": "2026-11-06", "read_date_basis": "the record version as_of", "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)", "state": "sourced", "value": "DK0010272202" }, "website": { "market": "DK", "state": "not_on_record" } }, "licensed": { "columns": [ "licensor", "entitlement", "title", "date", "source" ], "rows": [], "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded." }, "lifecycle": { "delisting": { "market": "DK", "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)", "state": "not_on_record" }, "domicile_change": { "market": "DK", "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)", "state": "not_on_record" }, "listing": { "market": "DK", "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)", "state": "not_on_record" }, "name_change": { "market": "DK", "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)", "state": "not_on_record" }, "segment_move": { "market": "DK", "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)", "state": "not_on_record" } }, "market": "DK", "node": "dk-cm-kg", "numbers_hash": "sha256:02d22a9b9c91602f1073e1dd977ed3f01f1334eb0e4fa76e669fe939e7787f0f", "open_research": { "read_date": "2026-11-12", "rows": [], "state": "none_found" }, "orderability": { "chapter_as_of": "2026-11-04", "client_categories": [], "determinable": false, "read": { "chapter": "https://dk.eu-cm-kg.ai/book/aio.json", "door": "https://dk.eu-cm-kg.ai/mcp", "tool": "get_orderability" }, "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category", "rule_version": "acm-68000/dk/mifid-ii-product-governance/r1", "section": "dk.aio.v5" }, "record": { "as_of": "2026-11-06", "url": "https://mcp.dk-cm-kg.ai/record/XCSE/DK0010272202", "version": 1 }, "schema": "research-numbers v0.1 (USR-01, 2026-11-11)", "status": { "read_date": "2026-11-09", "source": "https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=exchangeNewsFilterCPH|FirstNorthInformationCPH", "value": "listed, not halted" } }, "numbers_hash": "sha256:02d22a9b9c91602f1073e1dd977ed3f01f1334eb0e4fa76e669fe939e7787f0f", "path": "/dk/XCSE/DK0010272202", "schema": "research-page v0.1 (USR-02, 2026-11-11)", "sections": [ { "id": "identity", "text": "The issuer is Genmab A/S, listed on Nasdaq Copenhagen under ticker DK0010272202, with ISIN DK0010272202 and LEI 529900MTJPDPE4MHJ122. Security type, segment, sector and jurisdiction are not on the record. Listing status is listed, not halted.", "title": "Identity and listing" }, { "id": "disclosure", "text": "The record holds 91 filings on 74 filing days in the window 2025-11-06 to 2026-11-06. The median gap between filing days is 3 days, and the median latency from the latest filing to the record date is 1 day. Nasdaq Copenhagen has 119 issuers with a median cadence gap of 8.0 days, a median of 25 filings and a median latency of 4.0 days. Sector peer figures are not on record for this market. The latest filing is an Interim report (Q1 and Q3) dated 2026-11-05.", "title": "The disclosure read" }, { "id": "auditor", "text": "The auditor of record and its location are not on the record. Auditor changes are not on the record, as this register has no lifecycle type map yet.", "title": "Auditor" }, { "id": "events", "text": "Listing, delisting, name change, domicile change and segment move are not on the record, as this register has no lifecycle type map yet. The issuer is listed and not halted.", "title": "Events and halts" }, { "id": "orderability", "text": "The outcome is not determinable under rule version acm-68000/dk/mifid-ii-product-governance/r1, because the chapter's orderability section, as of 2026-11-04, carries no client categories.", "title": "Orderability" }, { "id": "coverage", "text": "No research houses were found on the issuer's investor-relations pages read.", "title": "Coverage" }, { "id": "open_research", "text": "No openly published research notes were found on the record.", "title": "Open research" }, { "id": "licensed", "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.", "title": "Licensed" }, { "id": "depth", "text": "The market's vintage is not sealed, and no issuer years are sealed. The market's earliest sealed date is not on the record, and the live record began date is not on the record.", "title": "As-of depth" }, { "id": "sources", "text": "6 source pages are named on this page; every value above carries its own source page and read date in the numbers.", "title": "Sources" } ], "sources": [ { "for": "identity.exchange", "source": "https://firds.esma.europa.eu/firds/" }, { "for": "identity.lei", "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download" }, { "for": "the disclosure lines", "source": "https://mcp.dk-cm-kg.ai/events/XCSE/DK0010272202" }, { "for": "the halt flag", "source": "https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=exchangeNewsFilterCPH|FirstNorthInformationCPH" }, { "for": "the orderability chapter", "source": "https://dk.eu-cm-kg.ai/book/aio.json" }, { "for": "the record", "source": "https://mcp.dk-cm-kg.ai/record/XCSE/DK0010272202" } ], "title": "Genmab A/S (DK0010272202) — research page", "writer": { "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers", "engine": "claude-haiku-5-5" } }